Robert Toal

We are three years away from when the hype machine surrounding decentralized trials first got revved up, but is interest really slowing? Join Clinical Leader Live on September 22nd as we check in with two sponsors to see how they are adapting to DCTs — hybrid, virtual, remote, home-based, or whatever the newest lingo is. We also dig into the FDA guidance and get the perspective of a site owner and advocate, Dr. Daniel Fox.

Questions Sponsors Should Ask When Selecting Tech Vendors For DCTs Elevar Therapeutics’ Jennifer Lee, RSM US’s Steve Kemler, and Janssen Clinical Innovation’s Bert Hartog recently discussed the challenges of new technology implementation. Here, Lee provides her top questions sponsors should be asking themselves before choosing a technology vendor.

Welcome to the Tuesday edition of the Clinical Leader newsletter, focusing on Clinical Trial Technology. Update your topic preferences to receive additional Clinical Leader newsletters on: Clinical Sites | Patient Centricity | Patient Recruitment (Monday) Decentralized Trials | Trial Management (Wednesday) Outsourcing Models | Regulatory & Compliance (Thursday) (Friday)